The Prostate Cancer market was impacted by nmCRPC1, mCSPC2 and mCRPC3 data presented during the ASCO Genitourinary Cancers Symposium (ASCO-GU) meeting in San Francisco, CA.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for ZYTIGA® (abiraterone), ERLEADA® (apalutamide), XTANDI® (enzalutamide), LYNPARZA® (olaparib) + KEYTRUDA® (pembrolizumab), YERVOY® (ipilimumab) + OPDIVO® (nivolumab), ZEJULA®, (niraparib) and darolutamide.

Companies presenting data included: AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Pfizer.

Get immediate access to this 54-slide report so you can make better decisions today and prepare for tomorrow.

Prostate Cancer Report ASCO GU 2019

ASCO Genitourinary Cancers Symposium

San Francisco, CA
Jan 17 to Jan 19

Share:

1. Non-metastatic Castration-resistant Prostate Cancer
2. Metastatic Castration-Sensitive Prostate Cancer
3. Metastatic Castration-resistant Prostate Cancer